Autolus Therapeutics plc (AUTL)
D
Pipeline Grade
Financial Position (from SEC Filings)
$132.4M
Cash & Equivalents
$65.3M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$450M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (7)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07400029 | A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | PHASE2 | Recruiting | 40 |
| NCT04404660 | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leu... | PHASE2 | Active Not Recruiting | 153 |
| NCT03628612 | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | PHASE2 | Enrolling By Invitation | 500 |
| NCT07053800 | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis | PHASE2 | Recruiting | 35 |
| NCT07053059 | Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With ... | PHASE2 | Recruiting | 30 |
| NCT06173518 | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic... | PHASE1 | Recruiting | 30 |
| NCT07139743 | Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | PHASE1 | Recruiting | 18 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.